Are Peptides Illegal in California? State Laws Explained

Are Peptides Illegal in California? What the Current Rules Actually Say

Confusion over the legal status of therapeutic peptides — from BPC-157 to CJC-1295 and semaglutide-adjacent compounds — has intensified as more Californians turn to wellness clinics, telehealth providers, and compounding pharmacies for peptide therapy. The short answer is that peptides are not universally illegal in California, but their legal status depends heavily on the specific peptide, how it is sourced, who prescribes it, and whether it is FDA-approved, compounded, or sold as an unapproved research chemical.

What Happened

California does not maintain a standalone "peptide law." Instead, peptide regulation flows primarily through two existing frameworks: the Sherman Food, Drug, and Cosmetic Law (California Health & Safety Code Section 109875 et seq.), which incorporates most federal drug-approval requirements by reference, and the rules enforced by the California State Board of Pharmacy governing compounding pharmacies. Recent legislative attention — including proposals affecting compounding oversight sometimes cited as SB 1442 — has focused on tightening quality and sourcing standards for compounded drug products, including peptides, rather than criminalizing peptides outright. Readers should verify the current bill number and status directly with the California Legislative Information website, as compounding-related legislation has been amended and renumbered across recent sessions.

In practice, this means a peptide can be legal when prescribed by a licensed practitioner and dispensed through a state-licensed compounding pharmacy, but illegal to sell or distribute outside that system — particularly for human use in products labeled "research use only."

State Context

California has historically taken an aggressive regulatory posture toward compounding pharmacies following high-profile national compounding safety incidents over the past decade. The Board of Pharmacy has adopted USP <795>, <797>, and <800> sterile and non-sterile compounding standards, and it conducts its own licensing and inspection regime that is often stricter than baseline federal expectations. This means California-licensed 503A pharmacies compounding peptides must meet both FDA and state-level sourcing, documentation, and purity requirements simultaneously.

Federal Comparison

At the federal level, the FDA — not the DEA — is the primary regulator of peptides, since most are not scheduled controlled substances. The DEA's role is limited mainly to peptides with hormone-like or performance-enhancing profiles that intersect with the Anabolic Steroid Control Act. The more significant federal constraint comes from the FDA's 503A and 503B Bulk Drug Substances Lists: several popular peptides, including BPC-157 and certain GLP-1 analogs outside FDA-approved formulations, have been excluded or challenged for compounding eligibility due to safety and effectiveness data gaps. California's Sherman Law generally mirrors these federal determinations, meaning a peptide deemed ineligible for compounding under FDA rules is typically also non-compoundable in California, even though the state has not passed a distinct statute naming that peptide.

Separately, federal law under Section 303(e) of the Food, Drug and Cosmetic Act makes it a felony to distribute human growth hormone for unapproved, non-prescribed uses — a provision California prosecutors can invoke alongside state consumer protection statutes.

Impact on Stakeholders

For consumers, the practical takeaway is that peptides purchased without a prescription from online "research chemical" vendors carry legal and safety risk, even if the peptide itself is not classified as a controlled substance. For prescribers, California's telehealth rules require a documented practitioner-patient relationship and adherence to medical board standards of care before prescribing peptide therapies, which limits the reach of out-of-state telehealth peptide clinics. For compounding pharmacies, increased scrutiny under recent legislative efforts means tighter recordkeeping, supplier verification, and potential exclusion of peptides removed from FDA bulk substance lists — a compliance burden that smaller independent pharmacies may struggle to absorb.

Key Dates and Next Steps

The FDA continues to review peptide nominations for its compounding bulk substances lists on a rolling basis, with several high-profile denials issued over the past two years affecting nationwide compounding practices, including in California. State-level compounding legislation remains active in Sacramento, and stakeholders should monitor the California State Board of Pharmacy's regulatory bulletins for updated guidance on peptide-specific compounding restrictions.

This overview is based on a regulatory guide originally published at peptidelaws.com and is intended for informational purposes only. It does not constitute legal or medical advice. Readers should consult the California Business and Professions Code, the Sherman Food, Drug, and Cosmetic Law, and current FDA compounding guidance, or seek qualified legal counsel, before making decisions involving peptide prescribing, compounding, or distribution.